Author:
Fouad F M,Ceimo J M,Tarazi R C,Bravo E L
Abstract
The early blood pressure and hemodynamic effects of the converting enzyme inhibitor (CEI), captopril, were compared in 23 hypertensive patients with those of a specific angiotensin II antagonist (AA), [Sar1, Thr8] A II. AA reduced mean arterial pressure (MAP) greater than 10 mm Hg only in seven of 23 patients vs 15 of 23 who responded to CEI (p less than 0.02). With both drugs, changes in MAP were not associated with significant changes in cardiac output (p greater than 0.10 for both drugs), but correlated with changes in systemic resistance (TPR); r = 0.84, p less than 0.001 for AA and r = 0.71, p less than 0.001 for CEI. Changes in TPR and MAP correlated significantly and inversely with log plasma renin activity in both instances; for AA, r = 0.829 and for CEI, r = -0.737; p less than 0.001 for both. The slopes of the two regression lines were not significantly different but the intercepts were +8.47 mm Hg for AA vs -10.17 mm Hg for CEI (p less than 0.001). This quantitative difference in response could be attributed either to an agonistic effect of [Sar1, Thr8] A II or to an additional vasodilator effect of captopril.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference8 articles.
1. The renin system in high blood pressure, from disbelief to reality: Converting-enzyme blockade for analysis and treatment
2. Renin, angiotensin inhibition and hypertensive disease. In Drug Therapeutics - Concepts for Physicians, edited by Melmon KL. New York;Bravo EL;Elsevier-North HollandInc,1979
3. Estimating renin participation in hypertension: Superiority of converting enzyme inhibitor over saralasin
4. Streeten DHP Anderson GH Freiberg JM Dalakos TG: Use of an angiotensinII antagonist (Saralasin) in the recognition of
5. ;"angiotensinogenic" hypertension. N Eng lJ 1975 Med 202: 657
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献